Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 23,839 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 5 A Clear all
Withdrawn Phase 1 Interventional

Pharmacokinetics and Safety of MNK-155 in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

NCT02767349
View directory record Official record
Conditions
Acute Pain
Interventions
MNK-155
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 3, 2026, 2:31 AM EDT
Active, not recruiting Phase 2 Interventional

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849
View directory record Official record
Conditions
Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
Palifermin, Lupron, peripheral blood stem cell transplantation, Total-Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Degarelix
Biological · Procedure · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

NCT00190749
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01280058
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Wild-type Reovirus
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 3 Interventional

Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight

NCT00114543
View directory record Official record
Conditions
Hyperbilirubinemia, Neonatal, Jaundice, Neonatal, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Aggressive Phototherapy 501-750g, Aggressive Phototherapy 751-1000g, Conservative Phototherapy 501-750g, Conservative Phototherapy 751-1000g
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 36 Hours
Enrollment
1,974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 3, 2026, 2:31 AM EDT
Completed No phase listed Observational

A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

NCT06734117
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction
Interventions
Elecsys® Troponin T hs Gen 6, Blood sample collection
Diagnostic Test · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
20 Years and older
Enrollment
5,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
El Centro, California • La Jolla, California • Gainesville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 3, 2026, 2:31 AM EDT
Terminated Phase 2 Interventional

S9709, Laser Surgery Plus Radiation Therapy in Treating Patients With Early Stage Cancer of the Larynx

NCT00003040
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
laser surgery, radiation therapy
Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Not applicable Interventional

PILI at Work a 5-Year Controlled Intervention Trial: Testing DVD Versus Group Delivery of a Weight-Loss Maintenance Intervention in Native Hawaiian- Serving Worksites

NCT01652989
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss, Weight Loss Maintenance
Interventions
Weight loss maintenance intervention face-to-face, Weight loss maintenance intervention delivered via DVD
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
Honolulu, Hawaii • Kailua-Kona, Hawaii • Kaunakakai, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Early Phase 1 Interventional Results available

Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

NCT00452868
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
Interventions
Donepezil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 3, 2026, 2:31 AM EDT
Active, not recruiting Phase 1 Interventional

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT03535350
View directory record Official record
Conditions
Glioblastoma
Interventions
Ibrutinib, Radiation, Temozolomide (TMZ)
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

NCT06862791
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD9550, AZD6234, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

NCT01770418
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Radiation with Concurrent Chemotherapy
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 3, 2026, 2:31 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs

NCT01424618
View directory record Official record
Conditions
Implantation, Embryo
Interventions
Leuprolide, Ganirelix
Drug
Lead sponsor
Kelly, Maureen, M.D.
Individual
Eligibility
18 Years to 52 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2011 · Synced Sep 3, 2026, 2:31 AM EDT
Active, not recruiting No phase listed Observational

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

NCT03251118
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
2 Years and older
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
37
States / cities
Lancaster, California • Mission Hills, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

NCT01959490
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
trastuzumab, Pertuzumab, docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, Bevacizumab
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 3, 2026, 2:31 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department

NCT05151510
View directory record Official record
Conditions
Myofascial Trigger Point Pain, Myofacial Pain
Interventions
Trigger point injection with 1% lidocaine, Lidocaine patch 5%
Procedure · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Terminated Early Phase 1 Interventional

Multimodal Pain Management Following Primary TKA

NCT02369523
View directory record Official record
Conditions
Pain
Interventions
Exparel, Ropivacaine cocktail (PIC), Bupivacaine
Drug
Lead sponsor
University of Utah
Other
Eligibility
40 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 3, 2026, 2:31 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

ENA-001 for Opioid Induced Respiratory Depression

NCT06967259
View directory record Official record
Conditions
Respiratory Depression
Interventions
ENA-001, Placebo Comparator
Drug
Lead sponsor
Enalare Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Overland Park, Kansas • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
75
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 3, 2026, 2:31 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

NCT00800280
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334, cimetidine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2010 · Synced Sep 3, 2026, 2:31 AM EDT
Recruiting Phase 2 Interventional

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

NCT02977780
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Neratinib, QBS10072S, Abemaciclib, CC-115
Drug
Lead sponsor
David Reardon, MD
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Recruiting Phase 2 Interventional

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

NCT04872543
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors (MPNST)
Interventions
ASTX727
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

NCT03361735
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix
Drug · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 3, 2026, 2:31 AM EDT
Not listed No phase listed Observational

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis

NCT01066208
View directory record Official record
Conditions
Wegener's Granulomatosis, Microscopic Polyangiitis, Churg Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu Arteritis
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years and older
Enrollment
3,588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 3, 2026, 2:31 AM EDT